Results 51 to 60 of about 20,614 (289)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Aims: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment.
Koichiro Matsumura MD, Takeshi Ijichi MD, Junko Morimoto MD, Kensuke Takabayashi MD, Mitsunori Miho MD, Keisuke Ueno MD, Eijiro Yagi MD, Toru Takase MD, Masafumi Ueno MD, Gaku Nakazawa MD   +9 more
doaj   +1 more source

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

Journal of the American Medical Association (JAMA), 2019
Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is
MD JamesL.JanuzziJr, PhD MargaretF.Prescott, Mdmphmba JavedButler, Mdmhs G.MichaelFelker, MD AlanS.Maisel, KevinMcCague, PhD AlexanderCamacho, Mdmph IleanaL.Piña, MD RicardoA.Rocha, Mdmph AmilM.Shah, PharmD KristinM.Williamson, MD ScottD.Solomon, PrescottButler Felker Januzzi, Pina Maisel, S. Rocha, McCague, Camacho, Camacho McCague, CamachoRocha Williamson Butler, ButlerFelker Prescott, Rocha Maisel, Solomon Williamson   +21 more
semanticscholar   +1 more source

Review Article : Sacubitril/valsartan use for the hospitalist [PDF]

, 2017
The mainstays of therapy for heart failure with reduced ejection fraction (HFrEF) have traditionally been angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers, aldosterone receptor antagonists, and ...
Hart, James, Littrell, Rachel, Padkins, Mitchell   +2 more
core   +1 more source

Sacubitril/valsartan:beyond natriuretic peptides [PDF]

, 2017
Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to potentially beneficial physiological effects.
Atlas, Bateman, Cannon, Carpentier, Cohn, Daniels, Dehlin, Dell’Italia, Emdin, Fan, Gainer, Graf, Hirata, Hubers, Ibebuogu, Kalra, Kon, Laine, Langenickel, Liang, Maack, McMurray, McMurray, McMurray, Meilandt, Miller, Mione, Mistry, Nagaya, Niederkofler, Ohno-Matsui, Okolicany, Packer, Parthasarathy, Pelc, Potter, Potter, Rechardt, Richards, Richards, Singh, Tom, Tsutamoto, Vardeny, Vodovar, Witherow, Wong, Yasojima, Zile   +48 more
core   +2 more sources

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts

Scientific Reports, 2021
Left ventricular remodeling due to pressure overload is associated with poor prognosis. Sacubitril/valsartan is the first-in-class Angiotensin Receptor Neprilysin Inhibitor and has been demonstrated to have superior beneficial effects in the settings of ...
Xiaofei Li, Julie Braza, Ulrike Mende, Gaurav Choudhary, Peng Zhang   +4 more
doaj   +1 more source

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact
Birju R. Rao, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi‐An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Mary C. Thomson, Peter Ubel, Neal W. Dickert   +11 more
doaj   +1 more source

Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction

JAMA cardiology, 2023
Key Points Question Can neprilysin inhibition improve markers of cardiovascular structure and function in patients with pre–heart failure with preserved ejection fraction?
M. Ledwidge, J. Dodd, F. Ryan, C. Sweeney, K. McDonald, Rebecca S Fox, Elizabeth Shorten, Shuaiwei Zhou, C. Watson, J. Gallagher, N. McVeigh, D. Murphy, K. McDonald   +12 more
semanticscholar   +1 more source

Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients [PDF]

, 2017
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of
Lang, C. C., Zaid Iskandar, M.
core   +2 more sources

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi, David J. Polhemus, Zhen Li, Daniel Yoo, Hiroshi Koiwaya, Amy Scarborough, Traci T. Goodchild, David J. Lefer   +7 more
doaj   +1 more source

Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure

Open Heart
Background Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan.
R. M. Neijenhuis, M. Nederend, Anna E van Groningen, M. Jongbloed, H. Vliegen, J. Jukema, P. Kiès, A. Egorova   +7 more
semanticscholar   +1 more source